Several cardiologists and radiologists praised pluses and downplayed minuses of Boston Scientific’s Eluvia drug-eluting vascular stent system in recent comments on the Centers for Medicare and Medicaid Services’ (CMS) hospital Inpatient Prospective Payment System (IPPS) regulation.
The stent, which was reviewed by the CMS as being potentially eligible for new technology add-on payments (NTAP) under the IPPS rules, is indicated for improving luminal diameter in the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?